Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
To determine what side effects and what clinical effects if any the administration of this
investigational product, IDEC-152 (an antibody against CD23 which is an important protein on
leukemia cells and certain cells in the body's immune system), has on the CLL patient
population.